Back to today’s briefing

Story perspectives

Samsung Bioepis Seizes 53% Market Share, Cuts Drug Costs

1/17/2025

46 6

Summary

Story summary

Samsung Bioepis' Q1 2025 Biosimilar Market Report showcases a remarkable 53% market share and a significant 53% drop in drug costs in the US, thanks to biosimilars. With 15 FDA approvals in 2024, oncology biosimilars lead the charge. Additionally, a Spanish study underscores the cost-effectiveness of a tocilizumab biosimilar for rheumatoid arthritis, promising hope for many patients.

1 of 1

Story summary

Samsung Bioepis' Q1 2025 Biosimilar Market Report showcases a remarkable 53% market share and a significant 53% drop in drug costs in the US, thanks to biosimilars. With 15 FDA approvals in 2024, oncology biosimilars lead the charge. Additionally, a Spanish study underscores the cost-effectiveness of a tocilizumab biosimilar for rheumatoid arthritis, promising hope for many patients.